ACRS VS AONC Stock Comparison

Performance

ACRS
10/100

ACRS returned -96.22% in the last 12 months. Based on SPY's performance of -11.17%, its performance is below average giving it a score of 10 of 100.

AONC
10/100

AONC returned -81.48% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ACRS
92/100

6 analysts offer 12-month price targets for ACRS. Together, they have an average target of 25, the most optimistic target put ACRS at 25 within 12-months and the most pessimistic has ACRS at 25.

AONC

"Analyst Price Targets" not found for AONC

Sentiment

ACRS
69/100

ACRS had a bullish sentiment score of 68.61% across Twitter and StockTwits over the last 12 months. It had an average of 32.27 posts, 12.68 comments, and 65.86 likes per day.

AONC

"Sentiment" not found for AONC

Technicals

ACRS
14/100

ACRS receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

AONC

"Technicals" not found for AONC

Earnings

ACRS
10/100

ACRS has missed earnings 8 times in the last 20 quarters.

AONC

"Earnings" not found for AONC

Profit

ACRS
10/100

Out of the last 20 quarters, ACRS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AONC

"Profit" not found for AONC

Volatility

ACRS
42/100

ACRS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

AONC
33/100

AONC has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Aclaris Therapeutics, Inc. Summary

Nasdaq / ACRS

Healthcare

Medical - Diagnostics & Research

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

American Oncology Network, Inc. Class A Common Stock Summary

Nasdaq / AONC

Healthcare

Medical - Care Facilities

American Oncology Network, Inc., through its subsidiaries, provides oncology services in the United States. The company provides various services to patients, including laboratory services for routine and specialized testing; in-house professional and technical pathology services with complete, accurate and timely pathology reports; in-house specialty pharmacy services with patient education, financial assistance, and 24/7 patient assistance; and care management support services including nutrition guidance. The company was incorporated in 2017 and is based in Fort Myers, Florida.

Power up your portfolio